Verition Fund Management
VNDA icon

Verition Fund Management’s Vanda Pharmaceuticals VNDA Stock Holding History

Verition Fund Management’s Portfolio VNDA Stock Details VNDA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-68,265
Closed -$313K – 3889
2025
Q1 		$313K Buy
68,265
+26,320
+63% +$123K ﹤0.01% 2846
2024
Q4 		$201K Buy
41,945
+1,660
+4% +$7.97K ﹤0.01% 2975
2024
Q3 		$189K Buy
40,285
+2,927
+8% +$15.7K ﹤0.01% 2900
2024
Q2 		$211K Buy
+37,358
New +$193K ﹤0.01% 2562
2024
Q1 		– Sell
-86,500
Closed -$365K – 2994
2023
Q4 		$365K Sell
86,500
-147,400
-63% -$595K ﹤0.01% 1677
2023
Q3 		$1.01M Buy
+233,900
New +$1.3M 0.01% 1077
2021
Q2 		– Sell
-11,493
Closed -$173K – 2160
2021
Q1 		$173K Buy
+11,493
New +$186K ﹤0.01% 1372

Other funds holding VNDA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
KAM
Krensavage Asset Management New York $256M AUM 69.63% 1-Year Est. Return

Verition Fund Management's VNDA Position: Q2 2025 in Review

Verition Fund Management sold out of Vanda Pharmaceuticals (VNDA) in Q2 2025, closing a stake of 68,265 shares — an estimated $313K sold.

Verition Fund Management first reported a position in VNDA in Q1 2021 and held it in 7 quarters. The position peaked at $1.01M in Q3 2023. 139 funds tracked by Wall St. Rank hold VNDA as of Q2 2025.

  • Verition Fund Management reported no remaining Vanda Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
  • Verition Fund Management sold 68,265 Vanda Pharmaceuticals shares in Q2 2025, an estimated $313K.
  • Verition Fund Management first reported a position in Vanda Pharmaceuticals in Q1 2021 and held it in 7 quarters.
  • Verition Fund Management's Vanda Pharmaceuticals position peaked at $1.01M in Q3 2023.
  • 139 funds tracked by Wall St. Rank held Vanda Pharmaceuticals as of Q2 2025.

Based on Verition Fund Management's 13F filing for Q2 2025, filed 14 Aug 2025.